Logo

BioNanomatrix and NCI Sign CRADA to Measure DNA Damage from Radiation Therapy

Jan 22, 2007
NEW YORK (GenomeWeb News) - Genome imaging company BioNanomatrix will work with the National Cancer Institute to develop technology to measure DNA damage caused by ionizing radiation therapy in cancer treatment, the company said last week.
 
Under the terms of the multi-year Cooperative Research and Development Agreement with NCI’s Radiation Biology Branch, BioNanomatrix will use its Nanoanalyzer as the basis of a system for quantifying the extent of DNA damage during treatment.
 
Han Cao, chief scientific officer of BioNanomatrix, said in a statement that physicians are currently "hindered in their efforts to deliver an optimal dose by a lack of information on the extent of damage to the patient from the radiation already administered."
 
The Nanoanalyzer uses a nanofluid array to unwind DNA into a linear form, which can be evaluated to identify specific DNA aberrations, BioNanomatrix said.
 
Financial terms of the agreement were not released.

Breaking News
The Scan

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.

Study Presents New Insights Into How Cancer Cells Overcome Telomere Shortening

Researchers report in Nucleic Acids Research that ATRX-deficient cancer cells have increased activity of the alternative lengthening of telomeres pathway.

Researchers Link Telomere Length With Alzheimer's Disease

Within UK Biobank participants, longer leukocyte telomere length is associated with a reduced risk of dementia, according to a new study in PLOS One.

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.